ID   Kasumi-6
AC   CVCL_0614
SY   KASUMI-6; KASUMI6
DR   CLO; CLO_0007072
DR   ArrayExpress; E-MTAB-2770
DR   ATCC; CRL-2775
DR   BioSample; SAMN03471785
DR   BioSample; SAMN10988477
DR   cancercelllines; CVCL_0614
DR   Cell_Model_Passport; SIDM01695
DR   DepMap; ACH-000166
DR   DSMZ; ACC-686
DR   DSMZCellDive; ACC-686
DR   GEO; GSM743415
DR   GEO; GSM887199
DR   GEO; GSM888272
DR   GEO; GSM1374592
DR   GEO; GSM4254134
DR   IARC_TP53; 28325
DR   JCRB; JCRB1024
DR   JCRB; NIHS0314
DR   LiGeA; CCLE_218
DR   PharmacoDB; Kasumi6_736_2019
DR   Progenetix; CVCL_0614
DR   Wikidata; Q54899523
RX   PubMed=12508245;
RX   PubMed=22460905;
RX   PubMed=30285677;
RX   PubMed=30629668;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31395879;
RX   PubMed=32180206;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: TCGA-110-CL cell line panel.
CC   Population: Japanese and Korean.
CC   Doubling time: ~70 hours (DSMZ=ACC-686).
CC   Sequence variation: Mutation; HGNC; 1833; CEBPA; Simple; p.Arg306Pro (c.917G>C); Zygosity=Heterozygous (PubMed=12508245; DepMap).
CC   Sequence variation: Mutation; HGNC; 3765; FLT3; Unexplicit; Internal tandem duplication (FLT3-ITD); ClinVar=VCV000016270; Zygosity=Unspecified (PubMed=32180206).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234Asp (c.700T>G); ClinVar=VCV000219759; Zygosity=Homozygous (DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.79%; Native American=0%; East Asian, North=75.55%; East Asian, South=23.65%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Discontinued: JCRB; NIHS0314; true.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): ATCC; DSMZ; JCRB
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 8,12
ST   D16S539: 9,10
ST   D18S51: 16
ST   D19S433: 13,15
ST   D21S11: 30,30.2
ST   D2S1338: 17,22
ST   D3S1358: 16,17
ST   D5S818: 11
ST   D7S820: 9,11
ST   D8S1179: 14,15
ST   FGA: 24,25
ST   Penta D: 11,12
ST   Penta E: 5,12
ST   TH01: 6,9
ST   TPOX: 8,9
ST   vWA: 17
DI   NCIt; C9154; Adult acute myeloid leukemia
DI   ORDO; Orphanet_519; Acute myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   64Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 29
//
RX   PubMed=12508245; DOI=10.1002/gcc.10161;
RA   Asou H., Gombart A.F., Takeuchi S., Tanaka H., Tanioka M., Matsui H.,
RA   Kimura A., Inaba T., Koeffler H.P.;
RT   "Establishment of the acute myeloid leukemia cell line Kasumi-6 from a
RT   patient with a dominant-negative mutation in the DNA-binding region of
RT   the C/EBPalpha gene.";
RL   Genes Chromosomes Cancer 36:167-174(2003).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31395879; DOI=10.1038/s41467-019-11415-2;
RA   Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M.,
RA   van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.;
RT   "Comprehensive transcriptomic analysis of cell lines as models of
RT   primary tumors across 22 tumor types.";
RL   Nat. Commun. 10:3574.1-3574.11(2019).
//
RX   PubMed=32180206; DOI=10.1007/s13577-020-00347-5;
RA   Kasai F., Asou H., Ozawa M., Kobayashi K., Kuramitsu H., Satoh M.,
RA   Kohara A., Kaneko Y., Kawamura M.;
RT   "Kasumi leukemia cell lines: characterization of tumor genomes with
RT   ethnic origin and scales of genomic alterations.";
RL   Hum. Cell 33:868-876(2020).
//